Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7319319 | 0.88 | MME (0.55) | MMEMMP1 | |
| SCHEMBL7323618 | 0.88 | MME (0.55) | MMEMMP1 | |
| SCHEMBL7446467 | 0.80 | MME (0.55) | MMEMMP1 | |
| SCHEMBL7450171 | 0.79 | MME (0.67) | MMEMMP1 | |
| SCHEMBL7327458 | 0.78 | MME (0.45) | MMEMMP1 | |
| SCHEMBL9753811 | 0.76 | MME (0.59) | MMEMMP1 | |
| SCHEMBL7293723 | 0.76 | ACE (0.60) | MMEMMP1 | |
| SCHEMBL7293716 | 0.76 | ACE (0.60) | MMEMMP1 | |
| SCHEMBL9753816 | 0.76 | MME (0.59) | MMEMMP1 | |
| SCHEMBL9753807 | 0.76 | MME (0.59) | MMEMMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200038379-A1 | PHARMACEUTICAL COMPOSITION | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2020-02-06 | — | — | US | claimed |
| CN-110237072-A | The preparation method of pharmaceutical composition | 武汉朗来科技发展有限公司 | 2019-09-17 | — | — | CN | claimed |
| WO-2019170136-A1 | PHARMACEUTICAL FORMULATION AND USE THEREOF | 武汉朗来科技发展有限公司 | 2019-09-12 | — | — | WO | claimed |
| WO-2019170135-A1 | MEDICINE COMPOSITION PREPARATION METHOD | 武汉朗来科技发展有限公司 | 2019-09-12 | — | — | WO | claimed |
| US-20190275046-A1 | NOVEL COMBINATION | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-09-12 | — | — | US | claimed |
| EP-3524250-A1 | PHARMACEUTICAL COMPOSITION | Wuhan LL Science And Technology Development Co., Ltd. (CN) | 2019-08-14 | — | — | EP | claimed |
| WO-2018211479-A1 | STABILIZED COMPOSITIONS OF ANGIOTENSIN II INHIBITORS AND NEUTRAL ENDOPEPTIDASE INHIBITORS AND PROCESS FOR PREPARATION THEREOF | LUPIN LIMITED (IN) | 2018-11-22 | — | — | WO | claimed |
| US-20160038494-A1 | NOVEL COMBINATION | INTRA-CELLULAR THERAPIES, INC. | 2016-02-11 | — | — | US | claimed |
| US-20120138506-A1 | METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITION | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | claimed |
| JP-4820056-B2 | — | — | 2011-11-24 | — | — | JP | claimed |
| WO-2003059345-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING VALSARTAN AND NEP INHIBITORS | NOVARTIS AG (CH) | 2003-07-24 | — | — | WO | claimed |
| US-5389610-A | For cardiovascular disorders | SCHERING CORPORATION (US) | 1995-02-14 | — | — | US | claimed |
| EP-0605589-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NATRIURETIC PEPTIDES OR NEUTRAL ENDOPEPTIDASE INHIBITORS FOR TREATING OR PREVENTING MYOINTIMAL PROLIFERATION | SCHERING CORPORATION (US) | 1994-07-13 | — | — | EP | claimed |
| WO-1993010773-A1 | USE OF NEUTRAL ENDOPEPTIDASE INHIBITORS IN THE TREATMENT OF LEFT VENTRICULAR HYPERTROPHY | SCHERING-PLOUGH S.P.A. (IT) | 1993-06-10 | — | — | WO | claimed |
| WO-1993005809-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NATRIURETIC PEPTIDES OR NEUTRAL ENDOPEPTIDASE INHIBITORS FOR TREATING OR PREVENTING MYOINTIMAL PROLIFERATION | SCHERING CORPORATION (US) | 1993-04-01 | — | — | WO | claimed |
| EP-0533084-A1 | Pharmaceutical compositions comprising natriuretic peptides or neutral endopeptidase inhibitors for treating and preventing myointimal proliferation | SCHERING CORPORATION (US) | 1993-03-24 | — | — | EP | claimed |
| WO-1992018159-A1 | USE OF NEUTRAL ENDOPEPTIDASE INHIBITORS IN THE TREATMENT OF NEPHROTOXICITY | SCHERING CORPORATION (US) | 1992-10-29 | — | — | WO | claimed |
| EP-0509442-A1 | Use of neutral endopeptidase inhibitors in the treatment of nephrotoxicity | SCHERING CORPORATION (US) | 1992-10-21 | — | — | EP | claimed |
| EP-0502075-A1 | CARBOXYALKYLCARBONYL AMINOACID ENDOPEPTIDASE INHIBITORS | SCHERING CORPORATION (US) | 1992-09-09 | — | — | EP | claimed |
| WO-1991007386-A1 | CARBOXYALKYLCARBONYL AMINOACID ENDOPEPTIDASE INHIBITORS | SCHERING CORPORATION (US) | 1991-05-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120138506-A1 | METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITION | REN, MME, ACE | MME 2/4885MMP1 258/4885 |
| US-20160038494-A1 | NOVEL COMBINATION | PDE5A, PDE2A, PDE3A | MME 12/4885MMP1 118/4885 |
| US-20200038379-A1 | PHARMACEUTICAL COMPOSITION | MME, ANPEP, TMPRSS15 | MME 1/4885MMP1 243/4885 |
| US-20190275046-A1 | NOVEL COMBINATION | PDE5A, PDE2A, PDE3A | MME 12/4885MMP1 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.